A new NYU Stern report adds weight to a growing concern: private equity’s role in healthcare is no longer just controversial—it’s becoming a regulatory flashpoint.
After more than $1 trillion in PE-driven healthcare deals over the past decade, the findings point to systemic risks:
- Higher complication rates and mortality in some settings
- Reduced staffing levels
- A 10x higher risk of bankruptcy among PE-backed providers
The core issue isn’t just ownership—it’s misalignment.
👉 A financial model built on leverage, returns, and exit timelines is increasingly clashing with a sector defined by continuity, access, and patient outcomes
High-profile bankruptcies (e.g., Steward, Prospect) highlight the downstream impact—especially in rural and underserved communities, where closures hit hardest.
But the report stops short of calling for a ban. Instead, it signals a shift toward controlled participation:
- Greater transparency in ownership and outcomes
- Limits on debt-heavy financial structures
- Regulatory oversight on acquisitions and operations